Fundamental Analysis of ABSCI CORP(NASDAQ:ABSI) stock

Fundamental Rating

Taking everything into account, ABSI scores 3 out of 10 in our fundamental rating. ABSI was compared to 588 industry peers in the Biotechnology industry. The financial health of ABSI is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ABSI is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ABSI has reported negative net income.

In the past year ABSI has reported a negative cash flow from operations.

ABSI had negative earnings in each of the past 5 years.

In the past 5 years ABSI always reported negative operating cash flow.

1.2 Ratios

ABSI has a Return On Assets of -50.88%. This is comparable to the rest of the industry: ABSI outperforms 48.97% of its industry peers.

Looking at the Return On Equity, with a value of -62.76%, ABSI is in line with its industry, outperforming 59.76% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-50.88%
ROE	-62.76%
ROIC	N/A

ROA(3y)-35.93%

ROA(5y)-57.21%

ROE(3y)-43.06%

ROE(5y)-81.76%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ABSI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ABSI does not have a ROIC to compare to the WACC, probably because it is not profitable.

ABSI has more shares outstanding than it did 1 year ago.

Compared to 1 year ago, ABSI has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 4.23 indicates that ABSI is not in any danger for bankruptcy at the moment.

The Altman-Z score of ABSI (4.23) is better than 78.42% of its industry peers.

A Debt/Equity ratio of 0.03 indicates that ABSI is not too dependend on debt financing.

ABSI has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: ABSI outperforms 42.12% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	4.23

ROIC/WACCN/A

WACC9.21%

2.3 Liquidity

A Current Ratio of 4.08 indicates that ABSI has no problem at all paying its short term obligations.

The Current ratio of ABSI (4.08) is comparable to the rest of the industry.

ABSI has a Quick Ratio of 4.08. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of ABSI (4.08) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.08
Quick Ratio	4.08

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ABSI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.79%.

The Revenue has decreased by -0.56% in the past year.

Measured over the past years, ABSI shows a small growth in Revenue. The Revenue has been growing by 6.15% on average per year.

EPS 1Y (TTM)-3.79%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-20.95%

Revenue 1Y (TTM)-0.56%

Revenue growth 3Y6.15%

Revenue growth 5YN/A

Revenue growth Q2Q-78.33%

3.2 Future

Based on estimates for the next years, ABSI will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.52% on average per year.

ABSI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 76.60% yearly.

EPS Next Y29.85%

EPS Next 2Y17.11%

EPS Next 3Y15.96%

EPS Next 5Y18.52%

Revenue Next Year71.14%

Revenue Next 2Y93.95%

Revenue Next 3Y103.02%

Revenue Next 5Y76.6%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ABSI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ABSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ABSI's earnings are expected to grow with 15.96% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y17.11%

EPS Next 3Y15.96%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ABSI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ABSCI CORP

NASDAQ:ABSI (4/23/2024, 7:00:00 PM)

After market: 4.8 +0.09 (+1.91%)

4.71

+0.2 (+4.43%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap531.19M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-50.88%
ROE	-62.76%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.08
Quick Ratio	4.08
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-3.79%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y29.85%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-0.56%

Revenue growth 3Y6.15%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ABSCI CORP (ABSI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens